A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).

Trial Profile

A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BV-ICE
  • Most Recent Events

    • 14 Sep 2017 Planned number of patients changed from 30 to 42.
    • 06 Dec 2016 Initial results (n=16) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Nov 2016 According to Seattle Genetics media release, data will be presented at the 58th American Society of Hematology (ASH) Annual Meeting Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top